MedTrace Logo

Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia

NCT05145101 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-12-20

No results posted yet for this study

Summary

In this study the antibody response after vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23) in adults with chronic lymphocytic leukemia will be investigated.

Conditions

Interventions

BIOLOGICAL

Prevnar13

Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later

Sponsors & Collaborators

  • Hannah Garcia Garrido

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-07
Primary Completion
2022-03-31
Completion
2022-03-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05145101 on ClinicalTrials.gov